Double attack: CAR-T and stem cell transplant target tough lymphoma
NCT ID NCT07538635
First seen Apr 25, 2026 · Last updated Jun 09, 2026 · Updated 9 times
Summary
This study tests a powerful two-step treatment for people with a fast-growing blood cancer (large B-cell lymphoma) that has come back or not responded to standard therapy. About 20 adults will receive CAR-T cells (engineered immune cells) followed by a stem cell transplant. The goal is to see if this combination can control the cancer longer, though lifelong monitoring or additional treatment may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK R/R LBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhengjiang, 310022, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.